enexia tirzepatide FDA confirms shortage is still over, gives compounders a grace period Tirzepatide Injections for Medical Weight

J.SuditB

Setmelanotide (Imcivree) Setmelanotide is a melanocortin-4 receptor agonist indicated for chronic weight management in adult and pediatric patients six years and older, with obesity due to certain rare genetic disorders

Many insurance plans impose prior authorization, step-therapy requirements, or BMI/comorbidity restrictions, creating months-long treatment delays

This asset is highly complementary to our Phase 3 FSGS program and broadens our development footprint across the kidney disease continuum, from acute injury through to chronic disease." Dr Nina Webster, CEO & Managing Director, Dimerix Limited #Dimerix #KidneyDisease #RareDisease #Biopharma #DrugDevelopment #ClinicalTrials #Nephrology #PrecisionMedicine #HealthcareInnovation #Biotech To view or add a comment, sign in ICYMI: Early phase 1 data from Bambusa Therapeutics suggests #BBT001 delivered rapid, durable improvements in atopic dermatitis severity and itch, with sustained biomarker suppression, favorable safety, and the potential for dosing as infrequently as every 3 months